Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of “Hold” from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been given an average rating of “Hold” by the twenty analysts that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $10.53.

Several equities research analysts have issued reports on SAGE shares. Truist Financial dropped their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. TD Cowen cut their target price on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, November 21st. HC Wainwright reissued a “neutral” rating and issued a $14.00 target price on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Scotiabank dropped their price target on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research note on Wednesday, October 30th. Finally, Oppenheimer reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 30th.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $7.08 on Friday. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $27.67. The company’s fifty day simple moving average is $5.69 and its two-hundred day simple moving average is $7.47.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The firm had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $10.80 million. During the same quarter in the prior year, the company earned ($2.81) earnings per share. The business’s revenue for the quarter was up 337.1% compared to the same quarter last year. Research analysts anticipate that Sage Therapeutics will post -6.45 EPS for the current year.

Institutional Trading of Sage Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SAGE. Headlands Technologies LLC boosted its holdings in Sage Therapeutics by 245.3% in the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares in the last quarter. Creative Planning purchased a new stake in Sage Therapeutics during the 3rd quarter valued at about $88,000. SG Americas Securities LLC increased its stake in Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 8,228 shares in the last quarter. Finally, Quest Partners LLC raised its holdings in Sage Therapeutics by 14.5% in the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,486 shares during the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.